Citizens Maintains Market Outperform on Haemonetics, Raises Price Target to $144
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.
Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.
